Vermillion said this week that at its annual meeting on March 21, shareholders elected Robert Goggin to the company's board of directors.
Goggin, who was put forth as a candidate by a trio of dissident shareholders comprising himself, Gregory Novak, and George Bessenyei, defeated Vermillion's candidate Roberta Della Vedova, with 4,749,042 votes cast for Goggin compared to 3,938,399 for Vedova.
Goggin's election is the culmination of a year-long attempt by the trio to influence Vermillion management by winning seats on the company's board.
Quantitative digital pathology firm Definiens has appointed a new advisory board to provide independent advice on trends in tissue diagnostics and clinical digital pathology.
Members of the advisory board include Ron Andrews, president of medical sciences at Life Technologies and former CEO of Clarient and CEO of GE Molecular Diagnostics; Uwe Bicker, dean of the Medical Faculty Mannheim at the University of Heidelberg and a member of the board of directors of Sanofi; Manfred Dietel, director of the Institute of Pathology at Charité Berlin and chairman of the German Society for Pathology; Eric Glassy, medical director of Pathology Inc. and chairman of the Digital Pathology Working Group of the College of American Pathologists; and Gerd Binnig, founder and chief technology officer of Definiens.
Healthlinx said this week that non-executive chairman Greg Rice has resigned from the company's board.
Rice is a co-founder of the company and NHMRC principal research fellow at the University of Queensland’s Centre for Clinical Research.
VolitionRx, a Singapore-based developer of blood-based cancer diagnostics, has hired Jason Terrell as head of US operations.
Terrell, who will act as the company’s liaison with the US Food and Drug Administration, owns and operates a number of diagnostic laboratories in Texas within the Any Lab Test Now franchise. He has also served as a national franchise corporate medical director for Any Lab Test Now.